Critiquing the Critics on Orac’s Respectful Insolence blog: Part III

Burzynski: Cancer is Serious Business, Part II

http://scienceblogs.com/insolence/2013/03/14/five-things-i-learned-second-hand-from-the-recent-screening-of-burzynski-cancer-is-serious-business-part-2

#37 – Denice Walter – March 14

“Milk kills”

Yes, it does:

https://www.google.com/search?q=%22Milk+kills%22&hl=en&client=safari&tbm=isch&tbo=u&source=univ&sa=X&ei=gXFIUZOHOvi04APZ24DoCQ&ved=0CDIQsAQ&biw=320&bih=416

#38 – Sirhcton – March 14

“. . .he’s never, despite having had over 60 phase II trials, published a complete phase II trial. . .

To abuse a meme: “I don’t have to show you any stinkin’ data!”

Just continue to do what you do best … ignore the information that is already out there:

2/24/2013

http://www.skeptical.gb.net/blog/?p=1442

2/27/2013

http://www.skeptical.gb.net/blog/?p=1798

3/9/2013

http://www.thetwentyfirstfloor.com/?p=8001

#41 – Krebiozen – March 14

“Denice,
to Mikey, ‘guns don’t kill people, processed milk kills people’”

You should really enjoy THIS, then:

#42 – Bob G Los Angeles – March 14

To Herr Doktor:

“The next time they do one of these B2 shows, where they screen the film and take questions, why doesn’t somebody just ask for the data right then and there — How many patients over the course of the years, including the fraction who are still alive, the fraction who died, and the fraction whose survival is unknown?

They will get used to hearing that question and do their best to adapt, but just making stuff up will have consequences of its own”

Why not just ask Dolcefino ?

#43 – Mark Thorson – March 14

“I have never heard of ANTINEOPLASTONS,” said Yu Xiong, deputy president of the Shanghai Institute of Pharmaceutical Industry”

http://usa.chinadaily.com.cn/china/2012-02/02/content_14528005.htm

Why should we care what Yu Xiong knows or does NOT know?

http://www.zoominfo.com/#!search/profile/person?personId=596114575&targetid=profile

With a population of 1,344,130,000 – 2011, I guess he does NOT keep up with:

10/29/2010 – ANTINEOPLASTONS:

New Perspectives on Innovative Drug Discovery: An Overview

CHINA:
Beijing University of Chinese Medicine

Hong Kong Baptist University

Chinese Academy of Medical Science & Peking Union Medical College

Hong Kong Polytechnic University

Hong Kong University of Science & Technology

9/1/2010 Received
9/22/2010 Revised
10/28/2010 Accepted
10/29/2010

(pg. 8 of 22 – actual pg. 457)
Human-derived compounds – ANTINEOPLASTONS and CDA-2

Urine and urine extracts have been used for therapeutic purposes for centuries, and the first identified active componentis 3 – phenylacetylamino – 2, 6 – piperidinedione (also called ANTINEOPLASTON A10)

http://ejournals.library.ualberta.ca/index.php/JPPS/article/download/9147/7453

10/1/2010 – ANTINEOPLASTON A10 – CHINA
http://www.springerlink.com/content/tj0177485773007t

(S)-2-((S)-2-(4-(3-[18F]fluoropropyl)benzamido)-3-phenylpropanamido)pentanedioic acid labeled with 18F

http://link.springer.com/article/10.1007%2Fs10967-010-0633-2?LI=true

Journal of Radioanalytical and Nuclear Chemistry
October 2010, Volume 286, Issue 1, pp 135-140
DOI 10.1007/s10967-010-0633-2

CHINA:
Key Laboratory of Radiopharmaceutical, College of Chemistry, Beijing Normal University, Beijing

PET Center of Xuan Wu Hospital, Beijing

Department of Nuclear Medicine, PUMC Hospital, CAMS and PUMC, Beijing

#Burzynski References: 5. – 6.

As degradation product of ANTINEOPLASTON A10 in vivo, phenylacetyl glutamine (PG) showed antitumor activities

According to literatures, we designed and radiosynthesized a phenylacetyl glutamine (PG) derivative, which was achieved under a mild reaction condition

Evaluations in vitro and in vivo were performed on tumor bearing mice

Excitingly, the radiochemical purity was 98%, and besides the best radiochemical yield was up to 46%

it showed satisfied stability in vitro and in vivo

the results revealed it might become a potential PET imaging agent for detecting tumors

4/15/2009 – ANTINEOPLASTON AS2-5 – CHINA
3/14/2008 – Epub

http://www.ncbi.nlm.nih.gov/m/pubmed/19339187

Bioorg Med Chem. 2009 Apr 15;17(8):3061-71. doi: 10.1016/j.bmc.2009.03.017. Epub 2009 Mar 14
Bioorganic & Medicinal Chemistry
Volume 17, Issue 8, 15 April 2009, Pages 3061–3071

School of Pharmaceutical Sciences, Shandong University, No. 44 WenhuaXi Road, Ji’nan, Shandong Province, PR CHINA

Novel aminopeptidase N inhibitors derived from ANTINEOPLASTON AS2-5 (Part II)

http://www.sciencedirect.com/science/article/pii/S0968089609002478

4/15/2009 – ANTINEOPLASTON AS2-5 – CHINA
3/6/2009 – ePub

http://www.ncbi.nlm.nih.gov/m/pubmed/19329328
Bioorg Med Chem. 2009 Apr 15;17(8):3053-60. doi: 10.1016/j.bmc.2009.02.063. Epub 2009 Mar 6
Bioorganic & Medicinal Chemistry
Volume 17, Issue 8, 15 April 2009, Pages 3053–3060

School of Pharmaceutical Sciences, Shandong University, No. 44 WenhuaXi Road, Ji’nan, Shandong Province, PR CHINA

Novel aminopeptidase N inhibitors derived from ANTINEOPLASTON AS2-5 (Part I)

http://www.sciencedirect.com/science/article/pii/S0968089609002041

2007- ANTINEOPLASTON A10 – CHINA

http://ar.iiarjournals.org/content/27/4B/2427.short

Induction of apoptosis in human hepatocellular carcinoma cells by synthetic ANTINEOPLASTON A10

ANTICANCER RESEARCH 27: 2427-2432 (2007)

1/24/2007 Received
3/27/2007 Accepted

School of Pharmaceutical Sciences, Shandong University, Jinan

Institute of Materia Medica, Shandong Academy of Medical Sciences, Jinan, CHINA

Department of Applied Biochemistry, Tokai University, Kanagawa

Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery,
Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

http://ar.iiarjournals.org/content/27/4B/2427.full.pdf

Burzynski References: 1, 3, 5, 13 and 15
Egypt ANTINEOPLASTON A-10 References: 2 and 20

1990 – ANTINEOPLASTON A10 – CHINA
http://www.ncbi.nlm.nih.gov/m/pubmed/2092962

Studies of the release rate and bioavailability of ANTINEOPLASTON A10 capsule

Shandong Medical University, Department of Pharmacy, Jinan, CHINA

Drugs Exp Clin Res 16 (7): 357-9 (1990), PMID .2092962
Drugs Exp Clin Res. 1990;16(7):357-9

1990 – ANTINEOPLASTON A10 – CHINA
http://www.ncbi.nlm.nih.gov/m/pubmed/2092961

Pharmacokinetic study of radioactive ANTINEOPLASTON A10 in rats and mice

Shandong Medical University, Department of Pharmacy, Jinan, CHINA

Drugs Exp Clin Res 16 (7): 351-5 (1990), PMID .2092961
Drugs Exp Clin Research
Drugs Exp Clin Res. 1990;16(7):351-5

#45 – Narad – March 14

““I have never heard of antineoplastons,” said Yu Xiong, deputy president of the Shanghai Institute of Pharmaceutical Industry

“Finally, barking up the right squirrel””

Another EPIC Burzynski Critic FAIL

#46 – herr doktor bimler – March 15

“From Mark Thorson’s link:

Li Qingchen, a doctor and member of Scientific Squirrels, a Chinese organization dedicated to the dissemination of scientific knowledge, said Thursday that the American Academy of Anti-Aging Medicine (A4M) has been using an unapproved cancer therapy to swindle Chinese patients

[...]

The Chinese representative office of A4M claimed on its website that it could offer a “breakthrough cancer therapy” developed by Dr. Stanislaw Burzynski, who asserts that cancer can be treated with ANTINEOPLASTONS, a group of amino acids and petides normally found in urine and blood

The organization also posted dozens of promotional videos and blogs on Sina Weibo, a popular Chinese microblogging site

Sounds like the international trade in snake oil has run into CITES regulations

What’s the story with AAAAM?

On first glance it’s a umbrella organisation for a heterogeneous mixture of shysters and charlatans, including Burzynski’s “Aminocare” sideline”

You mean ANTINEOPLASTONS which have the same main ingredient as CDA-2 (CDA-H or CDA-II) ?

“Phase I/II/III clinical trials of CDA-2 have been completed in China in 2003

In August 2004, the State Drug Administration (SDA) of China approved the use of CDA-2 as an anticancer drug in solid tumors.”
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0052117

“CDA-2 had been approved as a first class new anti-cancer drug by the SFDA of mainland China in 2004 through the effort of both side of Taiwan Strait.”

http://share.cjfu.com/supersite/?uid-43-action-viewspace-itemid-21

8/17/2005 – New anti-cancer medicine invented in east China

8/15/2005 – Professor Ming C. Liau, laboratory in Everlife Pharmaceutical Co,. Ltd. in Hefei, capital of east China’s Anhui Province

Professor Liau began his research on cancer since 1962

In 1975, he found out that methylation enzymes play a central role in the regulation of cell replication and differentiation, and by controlling these enzymes, cancer could be healed

http://english.people.com.cn/200508/17/eng20050817_202981.html

1986-1992 he worked and published with Burzynski

1992

LIAU. M.C.• Liau. C.P.• Burzynski. S.R.
Potentiation of induced terminal differentiation by phenylacetic acid and related chemicals
lnternat J Exptl Clin Chemother 1992;S:9-17

1992

LIAU, M.C., Luong, Y., Liau, C.P., Burzynski, S.R.
Prevention of drug induced DNA hypermethylation by antineoplaston components
Internal J Exptl Clin Chemother 1992;S:19-27

1992

LIAU, M.C., Luong, Y., Liau, C.P., Burzynski, S.R.
Prevention of drug-induced DNA hypermethylation by antineoplastons
Recent Advances in Chemotherapy
Adam D. (Ed), Futuramed Publishers. 1992; Munich, Germany

1990

Kampalath, B.N., LIAU, M.C., Burzynski, B., Burzynski, S.R.
Protective effect ofantineoplaston A10 in hepatocarcinogenesis induced by aflatoxin 81
Internal J Tissue Reactions 1990;12 (supp1):43-SO

1990

LIAU, M.C., Lee, S.S., Burzynski, S.R
Modulation of cancer methylation complex isoenzymes as a decisive factor in the induction of terminal differentiation mediated by antineoplaston A5
Internat J Tissue Reactions 1990; 12 (suppl): 27-36

1990

LIAU, M.C.• Ashraf. A.a.. Lee. S.S.• Hendry, L.B., Burzynski. S.R.
Riboflavin as a minor active anticancer component of antineoplaston A2 and A5
Internal J Tissue Reactions 1990;12:19-26

1990

LIAU, M.C., Lee, S.S., Burzynski, S.R.
Separation of active anticancer components of antineoplaston A2, A3, and A5
Internat J Tissue Reactions 1990; 12 (suppl): 1-17

1989

LIAU, M.C., Lee, S.S., Burzynski, S.R
Hypomethylation of nucleic acids:
A key to the induction of terminal
differentiation
Internal J Exptl Clin Chemother 1989;2:187-199

1988

LIAU, M.C., Lee, S.S, Burzynski, S.R
Differentiation inducing components of antineoplaston A5
Adv Exptl Clin Chemother. 1988; 6: 9-2S

1987

Kampalath, B.N., LIAU, M.C., Burzynski, B., Burzynski, S.R.
Chemoprevention by antineoplastonA10 ofbenzo (a) pyrene-induced pulmonary neoplasia
Drugs Exptl Clin Res 1987;13 (suppl 1):S1-SS_

1987

LIAU, M.C., Szopa, M., Burzynski, B., Burzynski, S.R
Chemoswveillance:
A novel concept of the natural defense mechanism against cancer
Drugs Exptl Cline Res 1987;13 (suppl 1):71-76

1987

LIAU, M.C., Szopa, M., Burzynski, B., Burzynski, S.R_
Quantitative assay of plasma and urinary peptides as an aid for the evaluation ofcancer patients undergoing antineoplaston therapy.
Drugs Exptl Clin Res 1987;13 (suppl 1) :6 1-7 0

1987

Ashraf, A Q., LIAU, M.C., Kampalath, B.N., Burzynski, S.R
Pharmacokinetic study of radioactive antineoplaston A10followingoraladministrationinrats_
DrugsExptlClinRes 1987;13(suppi1):4S-SO_

1986

Ashraf, AQ., LIAU, M.C., Mohabbat, M.O., Burzynski, S.R_
Preclinical studies ofantineoplastonA10 injections_
Drugs Exptl Clin Res 1986;12 (suppl 1):37-4S

1986

LIAU, M.C., Burzynski, S R
Altered methylation complex isoenzymes as selective targets for cancer chemotherapy
Drugs Exptl. Clin. Res. 12 (Suppl. 1):77-86
Drugs Exptl Clin Res 1986:12 (Suppl. 1):77-86

About these ads

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s